Drug intelligence / Profile preview

MG56 Mannosylated 3000

Development stage: Unknown
Modality: Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

MG56 Mannosylated 3000 appears to be a mannosylated therapeutic enzyme, likely designed for enhanced cellular uptake via mannose receptors. Mannosylation is a glycosylation process that adds mannose residues to proteins, which can target them to specific receptors like the mannose receptor (MMR). This targeting mechanism is particularly important for enzyme replacement therapies, as it can improve cellular uptake and therapeutic efficacy. The "3000" designation may refer to molecular weight or a specific formulation parameter.

Targets

MRC1 (Mannose Receptor C-type 1)

Beyond the preview

Go deeper on MG56 Mannosylated 3000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MG56 Mannosylated 3000.

Explore the full profile